ReviewInternational journal of molecular sciences2016
A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review.Histopathology · 2020Pooled it
- Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis.BMC cancer · 2020Pooled it
- Lypd6b depletion promotes CD8Nature communications · 2025Article
- Health-related quality of life and symptom burden in patients with melanoma during and after immune checkpoint inhibitor therapy - a pilot study.BMC cancer · 2025Article
- B cell-associated research in non-small cell lung cancer: a bibliometric analysis of current landscapes and future directions.Discover oncology · 2025Article
- Article
- Bispecific antibody simultaneously targeting AGR2 and PD1 mediates cytotoxic T-cell-induced antitumor response in AGR2-dependent manner and inhibits AGR2-induced PDL1 upregulation.Scientific reports · 2025Article
- Cracking Chordoma's Conundrum: Immune Checkpoints Provide a Potential Modality.International journal of medical sciences · 2025Article
- Transcriptomics analysis of LINC02202/XBP1 axis in melanoma: Implications for drug targeting and PD-1 monoclonal antibody efficacy.Journal of cellular and molecular medicine · 2024Article
- Hypopituitarism induced by pembrolizumab plus axitinib in the treatment of metastatic renal cell carcinoma: A case report.Oncology letters · 2024Article
- Article
- Mapping the epitope of PD-L1 to the paratope of the antibody durvalumab using molecular dynamics simulation.American journal of translational research · 2024Article
- Immunotherapy in melanoma: advances, pitfalls, and future perspectives.Frontiers in molecular biosciences · 2024Review
- Personalized tumor combination therapy optimization using the single-cell transcriptome.Genome medicine · 2023Article
- Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- Immune regulation and prognosis indicating ability of a newly constructed multi-genes containing signature in clear cell renal cell carcinoma.BMC cancer · 2023Article
- Review
- Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer.Cancers · 2022Review
- Research progress on immunotherapy in triple‑negative breast cancer (Review).International journal of oncology · 2022Review
- The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application.Frontiers in immunology · 2022Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interference of the binding of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) has become a new inspiring immunotherapy for resisting cancers. To date, the FDA has approved two PD-1 monoclonal antibody drugs against cancer as well as a monoclonal antibody for PD-L1. More PD-1 and PD-L1 monoclonal antibody drugs are on their way in clinical trials. In this review, we focused on the mechanism of the PD-1/PD-L1 signaling pathway and the monoclonal antibodies (mAbs) against PD-1 and PD-L1, which were approved by the FDA or are still in clinical trials. And also presented is the prospect of the PD-1/PD-L1 immune checkpoint blockade in the next generation of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.